Insulin-like Growth Factor 1 Long R3, commonly referred to as IGF-1 LR3, is a modified form of the endogenous growth factor IGF-1 that has been engineered for enhanced potency and extended biological activity in research applications. It is one of the most widely used growth factor variants in cell culture research and has been investigated in preclinical models across multiple fields including cell biology, oncology, and metabolic research.
What Is IGF-1?
Insulin-like Growth Factor 1 (IGF-1) is a 70-amino-acid polypeptide hormone that shares approximately 50% sequence homology with insulin. It is primarily produced by the liver in response to growth hormone stimulation and acts as a key mediator of the anabolic and growth-promoting effects of the growth hormone axis. IGF-1 signals through the IGF-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor that activates the PI3K/Akt and MAPK/ERK signaling cascades. These pathways regulate cell proliferation, differentiation, survival, and metabolism.
In physiological conditions, the vast majority of circulating IGF-1 is bound to IGF binding proteins (IGFBPs), a family of six high-affinity binding proteins that regulate IGF-1 bioavailability, half-life, and tissue distribution. IGFBP-3 is the predominant circulating binding protein and carries approximately 75% of circulating IGF-1 in a ternary complex with the acid-labile subunit (ALS). This protein binding limits the free concentration of IGF-1 available to interact with its receptor.
The LR3 Modification
IGF-1 LR3 is an 83-amino-acid analog of IGF-1 that incorporates two key modifications. First, the glutamic acid at position 3 of the native IGF-1 sequence is replaced with an arginine residue (the R3 substitution). Second, a 13-amino-acid extension peptide is added to the N-terminus (the L or Long extension). These modifications were specifically designed to reduce binding affinity for IGF binding proteins while preserving full agonist activity at the IGF-1 receptor.
The result of these modifications is a growth factor variant that is largely unbound in biological systems and therefore has significantly greater bioavailability than native IGF-1. In-vitro studies have demonstrated that IGF-1 LR3 has approximately two to three times the potency of native IGF-1 in cell proliferation assays, primarily because a higher proportion of the added growth factor is available to bind the IGF-1 receptor rather than being sequestered by binding proteins in the culture medium.
Cell Culture Research Applications
IGF-1 LR3 is extensively used as a supplement in cell culture media, particularly in serum-free and reduced-serum culture systems. Because serum contains high concentrations of IGFBPs, native IGF-1 added to serum-containing media is largely bound and inactive. IGF-1 LR3 circumvents this limitation by resisting IGFBP binding, making it a more effective growth factor supplement regardless of serum content.
In cell biology research, IGF-1 LR3 is used to study IGF-1R signaling, cell proliferation kinetics, anti-apoptotic pathways, and cellular metabolism. It is a standard component in defined media formulations for culture of many cell types including myoblasts, fibroblasts, epithelial cells, and various stem cell populations. Researchers studying the IGF-1 signaling axis use IGF-1 LR3 as a tool to activate the pathway maximally while controlling for the confounding effects of binding protein regulation.
Preclinical Research Areas
Beyond cell culture, IGF-1 LR3 has been used in animal model studies examining the effects of sustained IGF-1R activation on various tissues. Preclinical research has investigated its effects on skeletal muscle protein synthesis rates in rodent models, examining the relationship between IGF-1R signaling and muscle protein accretion through the PI3K/Akt/mTOR pathway. Studies have measured fractional synthesis rates, phosphorylation status of downstream signaling intermediates, and gene expression changes in muscle tissue following administration.
Additional preclinical research areas include metabolic studies examining the effects of IGF-1R activation on glucose uptake and insulin sensitivity, wound healing research examining effects on keratinocyte and fibroblast proliferation in animal models, and neuroscience research investigating IGF-1R signaling in neuronal survival and myelination. These studies have been conducted across multiple species and dosing paradigms.
Handling and Storage
IGF-1 LR3 is supplied as a lyophilized powder and requires careful handling due to its sensitivity to degradation. The lyophilized form should be stored at negative twenty degrees Celsius for long-term stability. For reconstitution, a mildly acidic buffer (such as 10 mM HCl or 0.1 M acetic acid) is recommended rather than neutral aqueous solvents, as IGF-1 LR3 has optimal solubility and stability at lower pH values. After dissolution in acidic buffer, the solution can be diluted into the final working buffer or culture medium.
Reconstituted IGF-1 LR3 should be aliquoted into single-use volumes and stored at negative twenty degrees Celsius to avoid repeated freeze-thaw cycles. Working aliquots may be stored at two to eight degrees Celsius for up to one week. As a polypeptide, IGF-1 LR3 can adsorb to glass and plastic surfaces, particularly at low concentrations. The addition of a carrier protein such as bovine serum albumin at 0.1% can reduce surface adsorption and improve recovery.
Quality Verification and Research Use
Researchers should verify the identity and purity of IGF-1 LR3 using the Certificate of Analysis, which should include HPLC purity data and mass spectrometry confirmation. Bioactivity can be confirmed using cell proliferation assays with IGF-1R-expressing cell lines. IGF-1 LR3 is sold exclusively for in-vitro and preclinical research applications. It is not intended for human use or therapeutic application. All data discussed in this article is derived from cell culture and animal model studies, and no claims of clinical relevance are made.